JOURNAL OF EXPERIMENTAL FICTIONBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL OF EXPERIMENTAL FICTION
Company Title:
Company Description:
Keywords to Search:
Company Address:	P O Box 5455,COMMERCE,GA,USA
ZIP Code: Postal Code:	31206
Telephone Number:	4787579385 (+1-478-757-9385)
Fax Number:
Website:	nutcrackermidga. org
Email:
USA SIC Code(Standard Industrial Classification Code):	731304
USA SIC Description:	Media Brokers
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
ATLANTA INTERNATIONAL DRAGWAY
JACKSON CITY MR SVC CTR
THE MANAGEMENT GROUP

Next company profile:
CHILDRENS INN AT NIH
INN AT SCHOFIELD BARRACKS
SPECTRUM ADVERTISING AGENCY

Company News:

About NEJM - The New England Journal of Medicine
With a 2023 Journal Impact Factor of 96 2, NEJM is a top-ranked, global, multi-specialty journal in the general medicine category [Source: 2023 Journal Impact Factor, Journal Citation Reports
The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor 21,22 Tezepelumab administered subcutaneously at a dose of 210 mg every 4
Lepodisiran - The New England Journal of Medicine
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease . . .
Targeted DNA Methylation Using Modified DNA Probes: A Potential Therapeutic Tool for Depression and Stress-Related Disorders, International Journal of Molecular Sciences, 26, 12, (5643), (2025
Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Tolebrutinib is an oral, brain-penetrant, and bioactive BTK inhibitor intended to target disease-associated microglia and B cells within the CNS in addition to their counterparts in the periphery